文献速递胸部肿瘤

序贯PD-(L)1阻断后使用奥希替尼时严重免疫相关不良事件常见

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib.
PubMed 文献 · Ann Oncol · 2019-01-01

在EGFR突变非小细胞肺癌患者中,序贯PD-(L)1阻断后使用奥希替尼者严重免疫相关不良事件发生率为15%(6/41,95%CI 7%-29%),其中PD-(L)1阻断后3个月内开始奥希替尼者发生率最高(5/21,24%,95%CI 10%-45%)。奥希替尼先于PD-(L)1或PD-(L)1后序贯其他EGFR-TKI者均未观察到严重irAE。

要点

  • 序贯PD-(L)1阻断后使用奥希替尼者严重irAE发生率为15%(6/41)。
  • PD-(L)1阻断后3个月内开始奥希替尼者严重irAE发生率为24%(5/21)。
  • 奥希替尼先于PD-(L)1或PD-(L)1后使用其他EGFR-TKI者未见严重irAE。

核心结论

  • PD-(L)1阻断后序贯奥希替尼与严重irAE相关,且在近期接受PD-(L)1阻断的患者中最常见。
  • 奥希替尼先于PD-(L)1阻断或PD-(L)1后序贯其他EGFR-TKI时未观察到irAE。
  • 该关联似乎为奥希替尼特异性,因使用其他EGFR-TKI时未发生严重irAE。

研究设计与样本

  • 研究纳入接受PD-(L)1阻断和EGFR-TKI治疗(不限药物或给药顺序)的EGFR突变NSCLC患者,总样本量n=126。
  • 通过查阅患者记录识别严重(NCI-CTCAE v5.0 3-4级)毒性。

主要发现

  • 所有序贯PD-(L)1阻断后使用奥希替尼的患者中,15%(6/41,95%CI 7%-29%)发生严重irAE。
  • PD-(L)1阻断后3个月内开始奥希替尼者严重irAE发生率为24%(5/21,95%CI 10%-45%)。
  • PD-(L)1阻断后>3-12个月开始奥希替尼者严重irAE发生率为13%(1/8,95%CI 0%-50%)。
  • PD-(L)1阻断后>12个月开始奥希替尼者严重irAE发生率为0%(0/12,95%CI 0%-28%)。
  • 奥希替尼后使用PD-(L)1者严重irAE发生率为0%(0/29,95%CI 0%-14%);PD-(L)1后使用其他EGFR-TKI(阿法替尼或厄洛替尼)者为0%(0/27,95%CI 0%-15%)。

关键数值与推荐

  • 严重irAE定义为NCI-CTCAE v5.0 3-4级毒性。
  • 所有发生irAE的患者均需使用类固醇,且大多数需住院治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Concurrent programmed death-ligand-1 (PD-(L)1) plus osimertinib is associated with severe immune related adverse events (irAE) in epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). Now that PD-(L)1 inhibitors are routinely used as adjuvant and first-line treatments, sequential PD-(L)1 inhibition followed by osimertinib use may become more frequent and have unforeseen serious toxicity. METHODS: We identified patients with EGFR-mutant NSCLC who were treated with PD-(L)1 blockade and EGFR- tyrosine kinase inhibitors (TKIs), irrespective of drug or sequence of administration (total n = 126). Patient records were reviewed to identify severe (NCI-CTCAE v5.0 grades 3-4) toxicity. RESULTS: Fifteen percent [6 of 41, 95% confidence interval (CI) 7% to 29%] of all patients treated with sequential PD-(L)1 blockade followed later by osimertinib developed a severe irAE. Severe irAEs were most common among those who began osimertinib within 3 months of prior PD-(L)1 blockade (5 of 21, 24%, 95% CI 10% to 45%), as compared with >3-12 months (1 of 8, 13%, 95% CI 0% to 50%), >12 months (0 of 12, 0%, 95% CI 0% to 28%). By contrast, no severe irAEs were identified among patients treated with osimertinib followed by PD-(L)1 (0 of 29, 95% CI 0% to 14%) or PD-(L)1 followed by other EGFR-TKIs (afatinib or erlotinib, 0 of 27, 95% CI 0% to 15%). IrAEs occurred at a median onset of 20 days after osimertinib (range 14-167 days). All patients with irAEs required steroids and most required hospitalization. CONCLUSION: PD-(L)1 blockade followed by osimertinib is associated with severe irAE and is most frequent among patients who recently received PD-(L)1 blockade. No irAEs were observed when osimertinib preceded PD-(L)1 blockade or when PD-(L)1 was followed by other EGFR-TKIs. This association appears to be specific to osimertinib, as no severe irAEs occurred with administration of other EGFR-TKIs.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Schoenfeld AJ, Arbour KC, Rizvi H, et al. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann Oncol. 2019. PMID: 30847464. doi:10.1093/annonc/mdz077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。